Research programme: ubiquitin ligases - Merck/Rigel

Drug Profile

Research programme: ubiquitin ligases - Merck/Rigel

Alternative Names: Ubiquitin ligases research programme - Merck/Rigel

Latest Information Update: 29 Mar 2010

Price : $50

At a glance

  • Originator Merck & Co; Rigel Pharmaceuticals
  • Class Ligases
  • Mechanism of Action Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Immunological disorders; Viral infections

Most Recent Events

  • 19 May 2006 This programme is still in active development
  • 18 Nov 2004 Preclinical trials in Immunological disorders in USA (unspecified route)
  • 18 Nov 2004 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top